Vantage logo

Finding the next Prevail

An $880m buyout by Lilly shows that some gene therapy companies have not yet priced themselves out of the market.

Vantage logo

Covid-19 stalls biotech flotations

Several young drug developers managed to float in the first quarter, but new issues dried up in March when coronavirus infected the markets. Is the game back on?